Imunon, Inc. (NASDAQ:IMNN – Get Free Report)’s stock price dropped 4.4% during trading on Thursday . The company traded as low as $0.78 and last traded at $0.80. 987,079 shares were traded during trading, a decline of 73% from the average daily volume of 3,671,681 shares. The stock had previously closed at $0.84.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on IMNN. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Imunon in a research note on Wednesday, March 26th. D. Boral Capital restated a “hold” rating on shares of Imunon in a report on Monday, May 19th. Wall Street Zen upgraded shares of Imunon to a “sell” rating in a report on Friday, June 6th. Finally, D Boral Capital lowered Imunon from a “strong-buy” rating to a “hold” rating in a report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $15.50.
Read Our Latest Analysis on Imunon
Imunon Stock Down 4.4%
Imunon (NASDAQ:IMNN – Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. Equities research analysts forecast that Imunon, Inc. will post -1.68 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Imunon
A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC lifted its position in shares of Imunon, Inc. (NASDAQ:IMNN – Free Report) by 10.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 139,505 shares of the company’s stock after purchasing an additional 13,570 shares during the period. Geode Capital Management LLC owned 0.96% of Imunon worth $133,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 4.47% of the company’s stock.
Imunon Company Profile
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Featured Articles
- Five stocks we like better than Imunon
- What Are Growth Stocks and Investing in Them
- Astera Labs: AI Infrastructure Play With Significant Growth Ahead
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Is IBM’s AI Transformation Powering a Sustained Rally?
- 3 Fintech Stocks With Good 2021 Prospects
- NVIDIA’s Stock Price Hits New Highs: This Is What’s Next
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.